Overview
Status
Active
Registry date
2022-04-08
Share capital
10,000.00 PLN
Registered address
ul. Domaniewska 37/2.43, 02-672 Warszawa, Poland
Electronic delivery address
AE:PL-77508-57929-GRHDG-19
Financials
Revenue history (in k)
Filing timeliness
2 of 3 financial statements were filed late (the longest delay 310 days for 2023).
- 202505/08/2026
- 202421/05/2025
- 202321/05/2025
Filed on timeDelayFiling deadline
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Results vs industry
Revenue
This companyUSD 1.48mMedianUSD 55.24kAverageUSD 2.70m
Net profit
This companyUSD -38.94kMedianUSD -1.27kAverageUSD -92.18k
Operating costs
This companyUSD 1.51mMedianUSD 65.85kAverageUSD 2.66m
Assets
This companyUSD 130.29kMedianUSD 133.19kAverageUSD 3.03m
Industry
Authorized Representatives
Lajos Sárosi – President of the Management Board
Manner of representation
Each member of the management board is independently authorised to submit declarations of will on behalf of the company.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Hungarotrial Gyógyszerkutatási Szolgáltató Zártkörûen Mûködõ Részvénytársaság | 200 | $2,701.24 | 100% |
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2022-07-01.
52 1090 1870 0000 0001 5049 9043
19 1090 1870 0000 0001 5068 9369
84 1090 1870 0000 0001 5049 9049
Debt
No entries in the National Debtors Register (KRZ).
Public aid
No public aid cases recorded in the last 10 years.
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| FamicordtxS.A. | $1,365,068.41 | famicordtx.com | ||
| Orphinic ScientificS.A. | $518,429.97 | orphinic.com | ||
| Proper Medical Writingsp. z o.o. | $464,661.64 | propermedicalwriting.com | ||
| Medicofarma BiotechS.A. | $314,882.33 | medicofarmabiotech.pl | ||
| Explorna Therapeuticssp. z o.o. | $304,662.00 | explorna.com | ||
| Frontline BiosciencesS.A. | $219,186.29 | frontlinebiosciences.com | ||
| AI Corelabsp. z o.o. | $128,365.55 | aicorelab.com | ||
| ModicaP.S.A. | $103,400.72 | modica.bio | ||
| WPD Pharmaceuticalssp. z o.o. | $90,822.78 | wpdpharmaceuticals.com | ||
| WPD PharmaceuticalsS.A. | $87,561.70 | wpdpharmaceuticals.pl |
FAQ
The main business activity of HT Research Pl focuses on research and experimental development on biotechnology.
The company was registered in the Polish National Court Register (KRS) on April 8, 2022.
The headquarters is located at: ul. Domaniewska 37, 02-672 Warszawa.
The share capital of the company is PLN 10,000 (approx. $2,701).
The latest available financial statement covers the period from January 1, 2024 to December 31, 2024.
In 2024, the company generated total revenue of $904,295, representing an increase of 97.2% compared to 2023.
No, in 2024 the company was not profitable, reporting a net loss of $186,985. For comparison, in 2023 the loss was $18,984, meaning the company increased its loss by 835.5%.
The largest operating cost category falls under employee remuneration. This category amounted to $686,154 in 2024, representing 64% of all operating expenses.
Last updated: 2026-10-07